PT2526943T - Formulação líquida compeendendo um agonista do recetor 2 (e.g. clonidina) e oxibutinina (agente anti-muscarínico) para tratamento de sialorreia - Google Patents
Formulação líquida compeendendo um agonista do recetor 2 (e.g. clonidina) e oxibutinina (agente anti-muscarínico) para tratamento de sialorreiaInfo
- Publication number
- PT2526943T PT2526943T PT121817738T PT12181773T PT2526943T PT 2526943 T PT2526943 T PT 2526943T PT 121817738 T PT121817738 T PT 121817738T PT 12181773 T PT12181773 T PT 12181773T PT 2526943 T PT2526943 T PT 2526943T
- Authority
- PT
- Portugal
- Prior art keywords
- sialorrhoea
- clonidin
- oxybutynin
- alpha
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0602857A GB0602857D0 (en) | 2006-02-13 | 2006-02-13 | The treatment of sialorrhoea |
| GB0602855A GB0602855D0 (en) | 2006-02-13 | 2006-02-13 | The Treatment Of Sialorrhoea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2526943T true PT2526943T (pt) | 2017-05-22 |
Family
ID=37944141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT121817738T PT2526943T (pt) | 2006-02-13 | 2007-02-12 | Formulação líquida compeendendo um agonista do recetor 2 (e.g. clonidina) e oxibutinina (agente anti-muscarínico) para tratamento de sialorreia |
| PT77053700T PT1986642E (pt) | 2006-02-13 | 2007-02-12 | Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT77053700T PT1986642E (pt) | 2006-02-13 | 2007-02-12 | Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8481583B2 (pt) |
| EP (2) | EP2526943B1 (pt) |
| JP (2) | JP5296557B2 (pt) |
| KR (1) | KR101370096B1 (pt) |
| AU (1) | AU2007216320B2 (pt) |
| CA (1) | CA2642850C (pt) |
| DK (2) | DK1986642T3 (pt) |
| ES (2) | ES2442694T3 (pt) |
| HK (1) | HK1129595A1 (pt) |
| MY (1) | MY145817A (pt) |
| NZ (1) | NZ570492A (pt) |
| PT (2) | PT2526943T (pt) |
| WO (1) | WO2007093824A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1986642T3 (da) * | 2006-02-13 | 2014-02-03 | Orient Pharma Samoa Co Ltd | Kombination af alfa-2-receptoragonist (clonidin) og et antimuscarinmiddel (oxybutynin) til behandling af sialorrhoea |
| GB0715790D0 (en) * | 2007-08-13 | 2007-09-26 | Summit Corp Plc | Drug combination for the treatment of sialorrhoea |
| US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
| CN102316850A (zh) * | 2009-02-11 | 2012-01-11 | 海格兰德公司 | 一种用于戒烟的口腔吸收尼古丁组合物 |
| KR101859486B1 (ko) * | 2009-05-15 | 2018-06-28 | 레크로파마, 인코포레이티드 | 설하용 덱스메데토미딘 조성물과 그의 사용 방법 |
| SG11201403094TA (en) | 2011-12-11 | 2014-10-30 | Recro Pharma Inc | Intranasal dexmedetomidine compositions and methods of use thereof |
| MA41689A (fr) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
| CN110337290A (zh) | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
| US11285141B2 (en) | 2017-07-20 | 2022-03-29 | Seinda Pharmaceutical Guangzhou Corporation | Composition and methods for the treatment of myopia |
| JP7488201B2 (ja) | 2018-06-27 | 2024-05-21 | バイオエクセル セラピューティクス，インコーポレイテッド | デクスメデトミジンを含むフィルム製剤、及びその作製方法 |
| CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312879A (en) * | 1980-08-14 | 1982-01-26 | Richardson-Merrell Inc. | Clonidine and lofexidine as antidiarrheal agents |
| US5578295A (en) * | 1995-04-28 | 1996-11-26 | The Procter & Gamble Company | Oral care compositions comprising certain substituted diphenyl ethers |
| AU1155399A (en) * | 1998-06-11 | 1999-12-30 | Arthur Janov | Use of clonidine for treatment of addictions, epilepsy, sleep disorders, eating disorders and migraines |
| WO2001008681A1 (en) * | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methods of administration of glycopyrrolate compositions |
| US6545046B2 (en) * | 2000-08-30 | 2003-04-08 | Theramax Inc. | Method for enhanced delivery of oxybutynin and compositions thereof |
| ATE432070T1 (de) * | 2003-01-22 | 2009-06-15 | Pfizer Health Ab | Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen |
| DK1986642T3 (da) * | 2006-02-13 | 2014-02-03 | Orient Pharma Samoa Co Ltd | Kombination af alfa-2-receptoragonist (clonidin) og et antimuscarinmiddel (oxybutynin) til behandling af sialorrhoea |
| GB0611241D0 (en) * | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
-
2007
- 2007-02-12 DK DK07705370.0T patent/DK1986642T3/da active
- 2007-02-12 ES ES07705370.0T patent/ES2442694T3/es active Active
- 2007-02-12 DK DK12181773.8T patent/DK2526943T3/en active
- 2007-02-12 AU AU2007216320A patent/AU2007216320B2/en not_active Ceased
- 2007-02-12 PT PT121817738T patent/PT2526943T/pt unknown
- 2007-02-12 KR KR1020087022049A patent/KR101370096B1/ko active IP Right Grant
- 2007-02-12 EP EP12181773.8A patent/EP2526943B1/en active Active
- 2007-02-12 PT PT77053700T patent/PT1986642E/pt unknown
- 2007-02-12 EP EP07705370.0A patent/EP1986642B1/en active Active
- 2007-02-12 US US12/279,217 patent/US8481583B2/en active Active
- 2007-02-12 CA CA2642850A patent/CA2642850C/en not_active Expired - Fee Related
- 2007-02-12 JP JP2008554857A patent/JP5296557B2/ja active Active
- 2007-02-12 MY MYPI20083081A patent/MY145817A/en unknown
- 2007-02-12 NZ NZ570492A patent/NZ570492A/en not_active IP Right Cessation
- 2007-02-12 WO PCT/GB2007/050057 patent/WO2007093824A1/en active Application Filing
- 2007-02-12 ES ES12181773.8T patent/ES2624577T3/es active Active
-
2009
- 2009-09-15 HK HK09108445.5A patent/HK1129595A1/zh not_active IP Right Cessation
-
2012
- 2012-08-23 US US13/593,173 patent/US8658683B2/en active Active - Reinstated
-
2013
- 2013-03-26 JP JP2013064062A patent/JP5744947B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8658683B2 (en) | 2014-02-25 |
| CA2642850A1 (en) | 2007-08-23 |
| NZ570492A (en) | 2011-08-26 |
| US20090221659A1 (en) | 2009-09-03 |
| PT1986642E (pt) | 2014-01-30 |
| JP5744947B2 (ja) | 2015-07-08 |
| JP2013144704A (ja) | 2013-07-25 |
| KR101370096B1 (ko) | 2014-03-04 |
| AU2007216320A1 (en) | 2007-08-23 |
| DK2526943T3 (en) | 2017-05-15 |
| MY145817A (en) | 2012-04-30 |
| EP1986642A1 (en) | 2008-11-05 |
| ES2624577T3 (es) | 2017-07-17 |
| AU2007216320B2 (en) | 2010-10-28 |
| ES2442694T3 (es) | 2014-02-12 |
| KR20090019765A (ko) | 2009-02-25 |
| DK1986642T3 (da) | 2014-02-03 |
| EP2526943B1 (en) | 2017-03-22 |
| JP5296557B2 (ja) | 2013-09-25 |
| HK1129595A1 (zh) | 2009-12-04 |
| JP2009526829A (ja) | 2009-07-23 |
| US20120316213A1 (en) | 2012-12-13 |
| EP1986642B1 (en) | 2013-11-13 |
| EP2526943A1 (en) | 2012-11-28 |
| WO2007093824A1 (en) | 2007-08-23 |
| CA2642850C (en) | 2015-06-30 |
| US8481583B2 (en) | 2013-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2526943T (pt) | Formulação líquida compeendendo um agonista do recetor 2 (e.g. clonidina) e oxibutinina (agente anti-muscarínico) para tratamento de sialorreia | |
| WO2007077561A3 (en) | Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents | |
| IL207532A0 (en) | Glp-1 receptor agonists and related phamaceutical ingredients for the treatment of cancer | |
| IL225198A (en) | Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes | |
| IL197833A0 (en) | Device for local and/or regional delivery employing liquid formulations of therapeutic agents | |
| EP2271301A4 (en) | METHODS AND COMPOSITIONS FOR THE DELIVERY OF AGENTS | |
| EP1986790A4 (en) | Liquid applicator and method for reducing the concentration of by-products from antiseptic | |
| PL2012765T5 (pl) | Płynne kompozycje zawierające fenylefrynę i acetaminofen oraz ich zastosowanie do leczenia chorób układu oddechowego | |
| EP2090880A4 (en) | PROBE LIGHT AND PUMP LIGHT MEASURING DEVICE, AND LOCAL PROBE MICROSCOPE APPARATUS USING THE DEVICE | |
| WO2007109135A3 (en) | Neuromedin u receptor agonists and uses thereof | |
| EP1900915A4 (en) | DEVICE FOR JUDGING A LIQUID REDUCING AGENT | |
| FR2952040B1 (fr) | Dispositif de distribution de liquide sous forme de gouttes | |
| IL213897A0 (en) | Ultrasound contrast agent dosage formulation | |
| EP2257543A4 (en) | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF | |
| GB2430428B (en) | Device and method for the metering of solutions | |
| IL206679A0 (en) | Modulators of chemokine receptors and processes for the preparation of the same | |
| GB0822158D0 (en) | Method,composition and device for the treatment of enzymes and saccharides disorders | |
| ZA200900125B (en) | Liquid formulation of pyrethroids | |
| WO2006116311A3 (en) | Opioid receptor agonist compounds and their use in treatment of pain | |
| EP2042912A4 (en) | LIQUID FOR CONTACT LENSES AND METHOD FOR HYDROPHILIZING A CONTACT LENS THROUGH ITS USE | |
| IL209698A (en) | Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox | |
| PL382264A1 (pl) | Urządzenie do kawitacyjnej obróbki mediów płynnych i sposób stosowania tego urządzenia | |
| IL195034A0 (en) | Liquid pharmaceutical formulation | |
| PL117634U1 (pl) | Urządzenie kriochirurgiczne na ciekły azot z zestawem krioaplikatorów kardiochirurgicznych Suwalskiego | |
| GB0821501D0 (en) | Method, composition, and device, for the treatment of enzymes and saccharides disorder |